AmericanPeptide
Catalog/PNC-27

PNC-27

Also known as PNC27

A p53-derived membrane-targeting peptide studied for selective necrosis of cancer cells in preclinical models.

Research refreshed

Overview

PNC-27 is a designed peptide that joins a fragment of the p53 protein (the region that binds HDM-2) to a membrane-residency peptide that anchors it in the cell membrane. In preclinical studies it is reported to induce necrosis selectively in cancer cells — which display HDM-2 at the membrane — while sparing normal cells, by forming membrane pores rather than acting through the classic p53 transcriptional pathway. It is an early anticancer research peptide with no clinical data and no approval.

Background

PNC-27 comes from the idea that the p53–HDM-2 interaction can be turned into a selective cancer-cell toxin. The peptide carries the p53 segment that binds HDM-2, attached to a “membrane-residency” peptide that lodges it in the plasma membrane. Cancer cells that present HDM-2 at their surface are reported to be killed by membrane-pore formation and necrosis, a mechanism distinct from p53’s usual role as a transcription factor.

The published work is laboratory and preclinical — cultured cancer cells and animal models — and the selectivity and mechanism remain areas of active study and debate. There is no clinical trial and no approval; PNC-27 is a research compound, and this page is a research and educational reference.

Mechanism

The p53 (12–26) HDM-2-binding domain, fused to a membrane-penetrating sequence, targets membrane-expressed HDM-2 on cancer cells and induces transmembrane pore formation and necrosis; proposed to spare normal cells that lack membrane HDM-2.

Key research findings

  • p53-derived design — uses the p53 HDM-2-binding domain fused to a membrane-anchoring peptide.
  • Membrane-pore necrosis — reported to kill cancer cells by pore formation, not the p53 transcriptional pathway.
  • Proposed selectivity — targets membrane HDM-2 said to be present on cancer but not normal cells (still under study).
  • Preclinical only — no clinical data; not FDA-approved.

How PNC-27 is made

Behind every vial of PNC-27 is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how PNC-27, specifically, is brought into being.

  1. On paper first

    PNC-27 begins not as a powder but as a specification. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.

  2. Built residue by residue

    PNC-27 is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.

  3. Purity is won here

    The crude mixture — PNC-27 plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.

  4. Proven, then protected

    A real batch of PNC-27 proves itself: identity confirmed by mass spectrometry, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of PNC-27 — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.

Walk the full synthesis pipeline

Handling, storage & why purity is hard

A ~32-residue chimeric peptide joining a p53 fragment to a membrane-penetrating sequence. The long, partly hydrophobic chain is aggregation-prone on the resin, so solid-phase synthesis of the full length is hard and deletion-sequence control dominates purity. A genuine spec needs mass spectrometry of the full construct, not just the p53 portion.

Demanding synthesis
Storage
Store lyophilized, frozen, and protected from light; keep reconstituted peptide cold and use quickly. A long, partly hydrophobic peptide is prone to aggregation in solution.
Handling
Reconstitute gently; the hydrophobic membrane-residency segment can make full dissolution difficult, and a certificate should confirm the full-length construct, not just the p53 fragment.

Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.

How peptides are made — the full pipeline

Research areas

  • Oncology (preclinical)
  • p53/HDM-2 biology
  • Membrane-targeting peptides

Research-area guides

Latest research

Recent clinical trials and publications mentioning PNC-27, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.

Frequently asked questions

What is PNC-27?+

A designed peptide combining a p53 fragment with a membrane-targeting sequence, studied for inducing necrosis in cancer cells in preclinical models.

How is it proposed to work?+

By anchoring the p53 HDM-2-binding domain in the cell membrane and targeting membrane-expressed HDM-2 on cancer cells, causing pore formation and necrosis rather than acting through p53 transcription.

Is there clinical evidence?+

No — the evidence is cell-culture and animal-model work; its selectivity and mechanism are still under study. There is no clinical trial.

Is it approved?+

No. This page is a research and educational reference, not medical advice.

Related peptides

Peptide Agent

Ask the Agent about PNC-27

Dosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.